Secondary loss of response (LoR) often precludes further use of infliximab in children with Crohn’s disease. Immunomodulators may reduce the incidence of LoR but their combination with infliximab presents safety concerns. We aimed to determine the long-term durability of infliximab response in paediatric Crohn’s, effect of immunomodulators on LoR, and secondarily the effect of infliximab on growth. We retrospectively audited patients on maintenance infliximab at a single centre. Data included height and weight, Paediatric Crohn’s Disease Activity Index (PCDAI), and immunomodulator use. 71 children (32% female, mean age 14.4 years) had been commenced on maintenance infliximab before July 2011. 89% had been on immunomodulators concurrently with infliximab. LoR occurred in 20 (28%), with a median time to LoR of 4.31 years. LoR was significantly increased in children who did not enter remission (PCDAI ≤ 10) after induction ( p < 0.05). LoR occurred more frequently in the 72% who ceased immunomodulators, but this failed to reach statistical significance ( p = 0.300). Height and weight SDS improved significantly on infliximab. Infliximab is a durable long-term therapy for paediatric Crohn’s refractory to conventional therapy. A large-magnitude increase in the rate of loss of response after immunomodulator cessation was not observed.
References
[1]
Yang, L.S.; Alex, G.; Catto-Smith, A.G. The use of biological agents in pediatric inflammatory bowel disease. Curr. Opin. Peds. 2012, 24, 609–614, doi:10.1097/MOP.0b013e3283574154.
[2]
Gouldthorpe, O.; Catto-Smith, A.G.; Alex, G. Biologics in paediatric Crohn’s Disease. Gastro Res. Prac 2011, 2011, 287574.
[3]
Yanai, H.; Hanauer, S.B. Assessing Response and Loss of Response to Biological Therapies in IBD. Am. J. Gastroenterol. 2011, 106, 685–98, doi:10.1038/ajg.2011.103.
[4]
Hyams, J.; Crandall, W.; Kugathasan, S.; Griffiths, A.; Olson, A.; Johanns, J.; Liu, G.; Travers, S.; Heuschkel, R.; Markowitz, J.; et al. Induction and Maintenance Infliximab Therapy for the Treatment of Moderate-to-Severe Crohn’s Disease in Children. Gastroenterology 2007, 132, 863–873, doi:10.1053/j.gastro.2006.12.003.
[5]
Hyams, J.S.; Lerer, T.; Griffiths, A.; Pfefferkorn, M.; Kugathasan, S.; Evans, J.; Otley, A.; Carvalho, R.; Mack, D.; Bousvaros, A.; et al. Long-term outcome of maintenance infliximab therapy in children with Crohn’s disease. Inflamm. Bowel Dis. 2009, 15, 816–822, doi:10.1002/ibd.20845.
[6]
Ruemmele, F.M.; Lachaux, A.; Cézard, J.P.; Morali, A.; Maurage, C.; Giniès, J.L.; Viola, S.; Goulet, O.; Lamireau, T.; Scaillon, M.; et al. Efficacy of infliximab in pediatric Crohn’s disease: A randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy. Inflamm. Bowel Dis. 2009, 15, 388–394, doi:10.1002/ibd.20788.
[7]
Colombel, J.F.; Sandborn, W.J.; Reinisch, W.; Mantzaris, G.J.; Kornbluth, A.; Rachmilewitz, D.; Lichtiger, S.; D’Haens, G.; Diamond, R.H.; Broussard, D.L.; et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N. Engl. J. Med. 2010, 362, 1383–1395, doi:10.1056/NEJMoa0904492.
[8]
Kotlyar, D.S.; Osterman, M.T.; Diamond, R.H.; Porter, D.; Blonski, W.C.; Wasik, M.; Sampat, S.; Mendizabal, M.; Lin, M.V.; Lichtenstein, G.R. A systematic review of factors that contribute to Hepatosplenic T-Cell Lymphoma in patients with Inflammatory Bowel Disease. Clin. Gastroenterol. Hepatol. 2011, 9, 36–41, doi:10.1016/j.cgh.2010.09.016.
Steenholdt, C.; Brynskov, J.; Thomsen, O.O.; Munck, L.K.; Fallingborg, J.; Christensen, L.A.; Pedersen, G.; Kjeldsen, J.; Jacobsen, B.A.; Oxholm, A.S.; et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: A randomised, controlled trial. Gut 2013, doi:10.1136/gutjnl-2013-305279.
[11]
Connell, W.; Andrews, J.M.; Brown, S.; Sparrow, M. Practical guidelines for treating inflammatory bowel disease safely with anti-tumour necrosis factor therapy in Australia. Intern. Med. J. 2010, 40, 139–149, doi:10.1111/j.1445-5994.2009.02122.x.
[12]
Motil, K.J.; Grand, R.J.; Davis-Kraft, L.; Ferlic, L.L.; Smith, E.O. Growth failure in children with inflammatory bowel disease: A prospective study. Gastroenterology 1993, 105, 681–691.
[13]
Sawczenko, A.; Sandhu, B.K. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch. Dis. Child. 2003, 88, 995–1000, doi:10.1136/adc.88.11.995.
[14]
Sawczenko, A.; Ballinger, A.B.; Savage, M.O.; Sanderson, I.R. Clinical features affecting final adult height in patients with pediatric-onset Crohn’s disease. Pediatrics 2006, 118, 124–129, doi:10.1542/peds.2005-2931.
[15]
MacRae, V.E.; Wong, S.C.; Farquharson, C.; Ahmed, S.F. Cytokine actions in growth disorders associated with pediatric chronic inflammatory diseases (review). Int. J. Mol. Med. 2006, 18, 1011–1018.
[16]
Wong, S.C.; Smyth, A.; McNeill, E.; Galloway, P.J.; Hassan, K.; McGrogan, P.; Ahmed, S.F. The growth hormone insulin-like growth factor 1 axis in children and adolescents with inflammatory bowel disease and growth retardation. Clin. Endocrinol. (Oxf.) 2010, 73, 220–228.
[17]
MacRae, V.E.; Farquharson, C.; Ahmed, S.F. The restricted potential for recovery of growth plate chondrogenesis and longitudinal bone growth following exposure to pro-inflammatory cytokines. J. Endocrinol. 2006, 189, 319–328, doi:10.1677/joe.1.06609.
[18]
Pfefferkorn, M.; Burke, G.; Griffiths, A.; Markowitz, J.; Rosh, J.; Mack, D.; Otley, A.; Kugathasan, S.; Evans, J.; Bousvaros, A.; et al. Growth abnormalities persist in newly diagnosed children with Crohn disease despite current treatment paradigms. J. Pediatr. Gastroenterol. Nutr. 2009, 48, 168–174, doi:10.1097/MPG.0b013e318175ca7f.
[19]
Walters, T.D.; Gilman, A.R.; Griffiths, A.M. Linear growth improves during infliximab therapy in children with chronically active severe Crohn’s disease. Inflamm. Bowel Dis. 2007, 13, 424–430, doi:10.1002/ibd.20069.
[20]
Van Assche, G.; Dignass, A.; Panes, J.; Beaugerie, L.; Karagiannis, J.; Allez, M.; Ochsenkuhn, T.; Orchard, T.; Rogler, G.; Louis, E.; et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Definitions and diagnosis. J. Crohns. Colitis 2010, 4, 7–27, doi:10.1016/j.crohns.2009.12.003.
[21]
Satsangi, J.; Silverberg, M.S.; Vermeire, S.; Colombel, J.F. The Montreal classification of inflammatory bowel disease: Controversies, consensus, and implications. Gut 2006, 55, 749–753, doi:10.1136/gut.2005.082909.
[22]
Available online: http://pbs.gov.au/medicine/item/4284L-5753T-5754W-5755X-5756Y-5757B-5758C-6397Q-6448J-6496X-9612X-9613Y-9617E-9654D-9674E (accessed on 2 October 2013).
[23]
Van Assche, G.; Magdelaine-Beuzelin, C.; D’Haens, G.; Baert, F.; Noman, M.; Vermeire, S.; Ternant, D.; Watier, H.; Paintaud, G.; Rutgeerts, P. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: A randomized trial. Gastroenterology 2008, 134, 1861–1868, doi:10.1053/j.gastro.2008.03.004.
[24]
Turner, D.; Griffiths, A.M.; Walters, T.D.; Seah, T.; Markowitz, J.; Pfefferkorn, M.; Keljo, D.; Otley, A.; Leleiko, N.S.; Mack, D.; et al. Appraisal of the pediatric Crohn’s disease activity index on four prospectively collected datasets: recommended cutoff values and clinimetric properties. Am. J. Gastroenterol. 2010, 105, 2085–2092, doi:10.1038/ajg.2010.143.
[25]
Rosh, J.R.; Lerer, T.; Markowitz, J.; Goli, S.R.; Mamula, P.; Noe, J.D.; Pfefferkorn, M.D.; Kelleher, K.T.; Griffiths, A.M.; Kugathasan, S.; et al. Retrospective evaluation of the safety and effect of adalimumab therapy (RESEAT) in pediatric Crohn’s disease. Am. J. Gastroenterol. 2009, 104, 3042–3049, doi:10.1038/ajg.2009.493.
[26]
Russell, R.K.; Wilson, M.L.; Loganathan, S.; Bourke, B.; Kiparissi, F.; Mahdi, G.; Torrente, F.; Rodrigues, A.; Davies, I.; Thomas, A.; et al. A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease. Aliment. Pharmacol. Ther. 2011, 33, 946–953, doi:10.1111/j.1365-2036.2011.04603.x.
[27]
Malik, S.; Wong, S.; Bishop, J.; Hassan, K.; McGrogan, P.; Ahmed, S.; Russell, R. Improvement in growth of children with crohn disease following anti-TNF-α therapy can be independent of pubertal progress and glucocorticoid reduction. J. Pediatr. Gastroenterol. Nutr. 2011, 52, 31–37, doi:10.1097/MPG.0b013e3181edd797.
[28]
Van Limbergen, J.; Russell, R.K.; Drummond, H.E.; Aldhous, M.C.; Round, N.K.; Nimmo, E.R.; Smith, L.; Gillett, P.M.; McGrogan, P.; Weaver, L.T.; et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 2008, 135, 1114–1122, doi:10.1053/j.gastro.2008.06.081.
[29]
Vernier-Massouille, G.; Balde, M.; Salleron, J.; Turck, D.; Dupas, J.L.; Mouterde, O.; Merle, V.; Salomez, J.L.; Branche, J.; Marti, R.; et al. Natural history of pediatric Crohn’s disease: A population-based cohort study. Gastroenterology 2008, 135, 1106–1113, doi:10.1053/j.gastro.2008.06.079.
